No matches
Type 2 Inflammation

Distinct Mechanisms Drive Inflammation and Itch in Chronic, Type 2 Inflammatory Diseases

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Brian Kim provides an overview of itch in type 2 inflammatory skin diseases and explains how the shared and unique mechanisms that drive inflammation and itch mediate each disease in distinct ways.
Brian Kim
MD
Brian Kim

Related resources

Clinical Manifestations Associated With Airway Remodeling in Asthma

Clinical Manifestations Associated With Airway Remodeling in Asthma

expert video
Impact of Exacerbations in COPD

Impact of Exacerbations in COPD

expert video
Role of Type 2 Cytokines in Asthma and COPD

Role of Type 2 Cytokines in Asthma and COPD

expert video
Exacerbations Lead to Worsening Lung Function

Exacerbations Lead to Worsening Lung Function

expert video
Unraveling the Link of Type 2 Inflammation and Airway Remodeling in Asthma

Unraveling the Link of Type 2 Inflammation and Airway Remodeling in Asthma

expert video
Mucus Plugging as a Potential Target in Asthma Management

Mucus Plugging as a Potential Target in Asthma Management

expert video
Multifaceted Role of IL-13 in Airway Remodeling

Multifaceted Role of IL-13 in Airway Remodeling

expert video
Pediatric Asthma Trajectory and Clinical Remission

Pediatric Asthma Trajectory and Clinical Remission

expert video
2025 ADVENT Forum | Joint Plenary Session: A View into the Life of Our Patients Video

2025 ADVENT Forum | Joint Plenary Session: A View into the Life of Our Patients Video

expert video
The Path to Nodules: Type 2 Inflammation at the Core of Chronic Itch and Fibrosis in Prurigo Nodularis

The Path to Nodules: Type 2 Inflammation at the Core of Chronic Itch and Fibrosis in Prurigo Nodularis

expert video
AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners

AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners

videoanimation
IL-4 Is the Primary Cytokine That Drives Th2 Cell Polarization and Amplifies Type 2 Inflammation

IL-4 Is the Primary Cytokine That Drives Th2 Cell Polarization and Amplifies Type 2 Inflammation

expert video
How Does Type 2 Inflammation Manifest in Chronic Diseases Across Different Organs?

How Does Type 2 Inflammation Manifest in Chronic Diseases Across Different Organs?

expert video
Type 2 Inflammatory Diseases Can Negatively Impact Patients and Their Caregivers

Type 2 Inflammatory Diseases Can Negatively Impact Patients and Their Caregivers

expert video
Coexisting Type 2 Inflammatory Diseases Can Add to the Patient Overall Disease Burden

Coexisting Type 2 Inflammatory Diseases Can Add to the Patient Overall Disease Burden

expert video
Type 2 Inflammatory Disease: What Are the Mechanisms that Contribute to the Development of Other Atopic Comorbidities?

Type 2 Inflammatory Disease: What Are the Mechanisms that Contribute to the Development of Other Atopic Comorbidities?

expert video
Itch in Chronic Inflammatory Skin Diseases: Histaminergic and Nonhistaminergic Mechanisms and Role of IL-4 as a Central Orchestrator in Promoting Neuronal Sensitization

Itch in Chronic Inflammatory Skin Diseases: Histaminergic and Nonhistaminergic Mechanisms and Role of IL-4 as a Central Orchestrator in Promoting Neuronal Sensitization

expert video
In Chronic Pruritic Skin Diseases, the Neuroimmune Axis Involves Dynamic Interactions Between Type 2 Inflammation and Sensory Nerves

In Chronic Pruritic Skin Diseases, the Neuroimmune Axis Involves Dynamic Interactions Between Type 2 Inflammation and Sensory Nerves

expert video
From Protective Type 2 Immunity to Aberrant Type 2 Inflammation

From Protective Type 2 Immunity to Aberrant Type 2 Inflammation

expert video
Underlying Type 2 Inflammation Drives a Chronic Itch-Scratch Cycle in Atopic Dermatitis

Underlying Type 2 Inflammation Drives a Chronic Itch-Scratch Cycle in Atopic Dermatitis

expert video

Learning objectives

  • Discuss the central role of type 2 inflammation in mediating itch in atopic dermatitis, prurigo nodularis, chronic spontaneous urticaria, and bullous pemphigoid and the shared and distinct neuroimmune mechanisms driving inflammation and itch severity
  • And discuss burden in each disease
Tags
disease backgroundexpert insightsmechanism of disease
MAT-US-2515115 v1.0-P Exp. Date: 08/26/2027

About this expert

Dermatology

Brian Kim

MD

Professor, Vice Chair of Research, and Site Chair of Mount Sinai West, Icahn School of Medicine, NY, US

See author’s profile
Brian Kim

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-US-2305040 v4.0 – P Expiration Date: 10/16/2027

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region